Citadel Advisors
AMRX icon

Citadel Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Citadel Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$507K Buy
+29,300
New +$402K ﹤0.01% 9836
2025
Q4 		– Sell
-23,400
Closed -$234K – 12573
2025
Q3 		$234K Sell
23,400
-79,900
-77% -$717K ﹤0.01% 10891
2025
Q2 		$836K Buy
103,300
+48,300
+88% +$364K ﹤0.01% 7484
2025
Q1 		$461K Buy
55,000
+54,400
+9,067% +$454K ﹤0.01% 8651
2024
Q4 		$4.75K Sell
600
-8,800
-94% -$73.8K ﹤0.01% 13903
2024
Q3 		$78.2K Sell
9,400
-1,100
-10% -$8.6K ﹤0.01% 11442
2024
Q2 		$66.7K Buy
10,500
+10,200
+3,400% +$64.8K ﹤0.01% 11433
2024
Q1 		$1.82K Sell
300
-6,300
-95% -$35.5K ﹤0.01% 14076
2023
Q4 		$40.1K Sell
6,600
-1,700
-20% -$7.57K ﹤0.01% 12015
2023
Q3 		$35K Buy
8,300
+2,400
+41% +$8.95K ﹤0.01% 12148
2023
Q2 		$18.3K Sell
5,900
-14,700
-71% -$31.3K ﹤0.01% 12810
2023
Q1 		$28.6K Sell
20,600
-1,100
-5% -$2.19K ﹤0.01% 12780
2022
Q4 		$43.2K Sell
21,700
-34,500
-61% -$77.3K ﹤0.01% 12312
2022
Q3 		$114K Sell
56,200
-2,200
-4% -$6.17K ﹤0.01% 10975
2022
Q2 		$186K Buy
58,400
+21,700
+59% +$78.6K ﹤0.01% 10776
2022
Q1 		$153K Buy
36,700
+18,800
+105% +$83.3K ﹤0.01% 11837
2021
Q4 		$86K Sell
17,900
-41,400
-70% -$206K ﹤0.01% 12856
2021
Q3 		$317K Buy
59,300
+43,200
+268% +$217K ﹤0.01% 10947
2021
Q2 		$82K Buy
16,100
+300
+2% +$1.71K ﹤0.01% 13059
2021
Q1 		$106K Sell
15,800
-54,800
-78% -$304K ﹤0.01% 12425
2020
Q4 		$323K Buy
70,600
+36,800
+109% +$163K ﹤0.01% 8942
2020
Q3 		$131K Buy
33,800
+1,300
+4% +$5.56K ﹤0.01% 9099
2020
Q2 		$155K Buy
32,500
+18,200
+127% +$74.9K ﹤0.01% 8714
2020
Q1 		$50K Buy
+14,300
New +$60.6K ﹤0.01% 9025
2019
Q3 		– Sell
-31,900
Closed -$229K – 9117
2019
Q2 		$229K Buy
+31,900
New +$326K ﹤0.01% 7999

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Citadel Advisors's AMRX Position: Q2 2026 in Review

Citadel Advisors increased its Amneal Pharmaceuticals (AMRX) stake by 94% in Q2 2026, buying an estimated $7.42M and bringing the position to 1,118,715 shares worth $19.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2635.

Citadel Advisors first reported a position in AMRX in Q2 2018 and has held it in 30 quarters since. The position peaked at $77.8M in Q4 2025. 310 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Citadel Advisors held 1,118,715 shares of Amneal Pharmaceuticals worth $19.4M as of Q2 2026.
  • Citadel Advisors bought 541,296 Amneal Pharmaceuticals shares in Q2 2026, an estimated $7.42M.
  • Amneal Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2635 holding.
  • Citadel Advisors first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 30 quarters since.
  • Citadel Advisors's Amneal Pharmaceuticals position peaked at $77.8M in Q4 2025.
  • 310 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.